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EFFECT OF HEALTH INSURANCE COVERAGE AND DEPRESSION ON
PRESCRIPTION MEDICATION USE IN PATIENTS WITH CHRONIC 
MEDICAL DISORDERS
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA
OBJECTIVES: Our objective was to study the association of health insurance coverage 
and of depression with prescription medication use in patients with chronic medical 
disorders (CMD). METHODS: For the retrospective analysis, we extracted data on
/18 year-old employed adults from the pooled 2004–5 Medical Expenditure Panel 
Survey. Data included ICD-9-CM-coded CMD (hyperlipidemia, heart-disease, arthri-
tis/other joint-disorders, chronic obstructive pulmonary disease, hypertension, or dia-
betes), depression, age, gender, race, poverty-level, health insurance, urban-residence, 
any depression treatment (psychotherapy or antidepressant of type selective serotonin
reuptake inhibitor, SSRI; Tricyclic, TCA; or nonSSRI/TCA), and one or more prescrip-
tion medication (yes/no). Weighted sample estimates and 95 percent conﬁ dence limits 
(CL) were calculated using the Taylor expansion method. In univariate logistic regres-
sion and in multivariate logistic regression analyses, after controlling for other charac-
teristics, we examined the association of health insurance coverage and depression with
prescription medication use in CMD patients. RESULTS: In univariate logistic regres-
sion, CMD patients with depression were more likely to have one or more prescription 
medications than those without depression (Odds Ratio, OR 2.99, 95% CL: 2.21–4.04, 
p  0.001). In multivariate logistic regression analyses, after adjusting for demographic
and other characteristics, one or more prescription medication use was less likely in
CMD patients who were uninsured (OR 0.97, 95% CL: 0.67–1.41) and in CMD 
patients with public insurance (OR 0.37, 95% CL: 0.30–0.46) each when compared
with CMD patients with private insurance (overall p  0.001). In multivariate logistic 
regression analyses, after adjusting for other covariates including any depression treat-
ment, depression was no longer signiﬁ cantly associated with one or more prescription 
medication use (p  0.69). CONCLUSIONS: Differences in the use of prescription
medications between CMD patients with public insurance and CMD patients with
private insurance warrant further study and the attention of payers and providers.
PMH66
ANTIDEPRESSANTS AND ANTIPSYCHOTICS USE IN CHILDREN-HAS
THE UTILIZATION CHANGED AFTER SAFETY WARNINGS?
Mehta S, Nagar SP, Aparasu R
University of Houston, Houston, TX, USA
OBJECTIVES: To evaluate annual utilization pattern of antidepressants and antipsy-
chotics in children, before and after safety warnings in 2004. METHODS: The 
2003–2005 National Ambulatory Medical Care Survey (NAMCS) and Outpatient 
Department component of National Hospital Ambulatory Medical Care Survey 
(NHAMCS) were used to evaluate visits involving antidepressants and antipsychotics 
medications prescribed for patients 20 years or younger. Prescription data from the
national surveys were combined to evaluate annual utilization trends. The annual visit 
estimates and percentages were calculated using inﬂ ation factor patient sampling
weight. RESULTS: According to NAMCS-NHAMCS, annual visit estimates involving
antidepressants were 7.35 million in 2003, 6.72 million in 2004 and 6.51 million in 
2005. The proportions of antidepressant-related visits were 3.37% in 2003, 3.12%
in 2004 and 2.81% in 2005. The annual visits for SSRI were 4.68 million, 3.55 
million, and 3.75 million in 2003, 2004 and 2005 respectively. Percentages of SSRI 
prescriptions in visits involving antidepressants were 63.67% in 2003, 52.82% in
2004 and 57.60% in 2005. Annual visits involving antipsychotics were 2.4 million in 
2003, 2.05 million in 2004 and 2.51 million in 2005. The proportions of antipsy-
chotic-related visits among all children visits were 1.09% in 2003, 0.95% in 2004 
and 1.08% in 2005. The ﬁ ndings revealed that annual prescribing pattern of antide-
pressants and antipsychotics in terms of visit estimates and utilization rates remained 
stable (p  0.05). Also there was no signiﬁ cant change in annual prescribing of SSRI.
Analysis of antidepressant and antipsychotic utilization trends among children with 
depression also revealed similar a pattern. CONCLUSIONS: There is no signiﬁ cant
change in annual utilization trends of antidepressants in children due to regulatory 
warnings. Also, safety warnings do not appear to have inﬂ uenced utilization pattern
of antipsychotics in children. More research is needed to evaluate patient-level changes 
in the management of antidepressant therapy due to regulatory warnings.
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ORAL SUPPLEMENTATION AND CONCOMITANT MEDICATION IN THE
TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL 
ANTIPSYCHOTICS
Ascher-Svanum H1, Peng X2, Montgomery W3, Faries DE2, Lawson AH1, Witte M2, 
Novick D4, Jemiai N5, Perrin E6
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA, 3Eli Lilly 
Australia Pty Ltd, West Ryde, Australia, 4Eli Lilly and Company, Windlesham, Surrey, UK, 5Eli
Lilly and Company, Erl Wood ELCL, UK, 6Eli Lilly and Company, Suresnes, France
OBJECTIVES: To assess the use of oral antipsychotics and other concomitant oral
medications – psychotropics and the anticholinergic benztropine—during the 1-year 
open-label treatment of schizophrenia with olanzapine long-acting injection (OLAI), 
and to compare with previously published rates for risperidone long-acting injection 
(RLAI). METHODS: One-year rates of concomitant oral medication use were drawn
from 2 comparable open-label, single-arm extension studies of patients with schizo-
phrenia treated with long-acting atypical antipsychotic medications: 1 for OLAI (n 
931), with extension of 3 OLAI clinical trials, and 1 for RLAI (n  371), with exten-
sion of 2 RLAI clinical trials (based on published 1-year data—Lindenmayer et al., 
Eur Neuropsychopharmacol. 2007;17:138–144). RESULTS: Supplementation with 
oral olanzapine occurred in 21% of OLAI-treated patients (median duration 10 days). 
Oral risperidone was supplemented – beyond the ﬁ rst 3 weeks of treatment in 45%-
83% of RLAI-treated patients (median duration not reported). Use of the anticholin-
ergic benztropine was low among OLAI-treated patients (3%, median duration 14 
days) and higher among RLAI-treated patients (31%-44%, median duration not 
reported). Lorazepam was used by 11% of OLAI-treated patients compared to 24%-
55% of RLAI-treated patients. Zolpidem was used by 4% of OLAI-treated patients 
and 11%-12% of RLAI-treated patients. CONCLUSIONS: Atypical antipsychotic 
therapies in long-acting injection formulations were found in this preliminary analysis 
to differ on concomitant use of oral atypical antipsychotic and other oral medications. 
OLAI therapy may require less oral supplementation compared to RLAI, thus offering 
a simpler treatment regimen. Though limited by cross-study comparisons and the need
for replication, the current ﬁ ndings may have important clinical and economic rami-
ﬁ cations as depot formulations are often chosen for persons previously nonadherent
to oral medication regimens.
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IMPACT OF FAMILY STRUCTURE ON STIMULANT USE AMONG
CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
Rabbani A, Alexander GC
University of Chicago, Chicago, IL, USA
OBJECTIVES: To examine the impact of family structure on pharmacologic stimulant 
use among children with Attention Deﬁ cit Hyperactivity Disorder (ADHD) 
METHODS: We examined pharmacologic stimulant use among children with ADHD 
using a nationally representative, population-based sample of the National Health 
Interview Survey from 1997 to 2003 linked with drug event ﬁ les from the Medical 
Expenditure Panel Survey from 1998 to 2005. We conducted stepwise multivariate
logistic regression to examine the likelihood of stimulant use among children ages 
2–17 years of age with a clinical diagnosis of ADHD after adjustment for sociodemo-
graphic (age, sex, race, income, health insurance, geographic region and metropolitan
area), health (self-reported physical and mental health status, mental disorders, health
care use), and family (single vs. dual parent household structure, parental education,
family size, and household income as a fraction of federal poverty line) characteristics. 
We also conducted stratiﬁ ed analyses to examine if family characteristics (e.g., mater-
nal education) had different impacts within single and dual parent households. 
RESULTS: Overall, an average of 37% (95% conﬁ dence interval 33%-41%) of chil-
dren with ADHD received at least one stimulant during the study period, and stimu-
lant used varied based on children’s sociodemographic and health characteristics. In 
multivariate analyses, associations between children’s household structure, parental
education, and stimulant use appeared to be mediated by access to care and children’s 
health status. However, in full multivariate models, there remained a robust associa-
tion between family size and stimulant use, with children from larger families signiﬁ -
cantly more likely to be using stimulants than their counterparts. CONCLUSIONS:
These ﬁ ndings highlight the inﬂ uence that non-clinical factors, such as family size, 
may have in mediating the use of pharmacologic therapies for children.
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THE IMPACT OF DEMOGRAPHICS AND INSURANCE ON QUALITY OF
CARE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN A 
CALIFORNIA MEDICAID PROGRAM
Nichol MB1, Wu J1, Knight TK1, Priest JL2, Cantrell CR2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle 
Park, NC, USA
OBJECTIVES: To describe quality of care and to investigate the factors associated with 
treatment modality in patients with major depressive disorder (MDD). METHODS:
California Medicaid administrative data from January 1 to June 30, 2004 were used
to identify patientsq18 years of age with a new episode of MDD. Quality of care
assessment was based on current clinical practice guidelines, using data from the diag-
nosis date to the last day of 2004. The assessment included the proportion of patients 
using antidepressants or psychotherapy and those non-adherent to medication (medica-
tion possession ratio 0.8). Logistic regressions were used to identify factors associated 
with use of antidepressants or psychotherapy. RESULTS: Of 5376 individuals who 
were identiﬁ ed as MDD, 2467(46%) received neither antidepressant medication nor
psychotherapy, 146(3%) had at least one psychotherapy session, 2535(47%) had any 
antidepressant prescription ﬁ ll, and 228(4%) used both antidepressants and psycho-
therapy. Patients of White race or those with Medicare/Medicaid dual eligibility (41%) 
were more likely to use selective serotonin reuptake inhibitors (SSRI) than comparison 
race groups (32% for Black, 35% for other than White or Black, p  0.0001) or non-
dually eligibles (36%, p  0.001). For patients using antidepressants, 89% were non-
adherent to their medication. Major factors associated with antidepressant use included
White race (OR:1.41, CI:1.26–1.59 vs. other than White and Black race), dual eligibil-
ity (OR:1.75, CI:1.55–1.98), a depression-related ofﬁ ce visit (OR:1.43, CI:1.27–1.60), 
a long-term care stay (OR:1.86, CI:1.34–1.25), and female gender (OR:1.14,
CI:1.01,1.29). Factors associated with use of psychotherapy included dual eligibility 
(OR:68.79, CI:39.24–120.60), a depression-related ofﬁ ce visit (OR:13.65, CI:8.59–
21.69), and a long-term care stay (OR:2.24, CI:1.58–3.18). CONCLUSIONS: These 
ﬁ ndings provide evidence of less than optimal care received by MDD patients from a 
California Medicaid program. Interventions tailored to individual characteristics (race
and gender), as well as those addressing mutable factors (such as dual eligibility) may
improve care in these patients.
